[admin]

Why Quantitative Oncology Immunoassay Testing Matters

Serum-based tumor marker testing sits at the center of modern cancer management. These assays are used to track disease progression, assess treatment response, and detect recurrence after treatment, since tumor markers are often proteins whose circulating levels change with tumor burden. For laboratories and clinical departments evaluating a quantitative oncology immunoassay platform, the core questions are consistent: how accurate is a single marker, when does a combined panel add value, and what instrument can deliver results quickly without complex sample handling. Poclight’s Tumor Marker product line, built around tPSA, fPSA, CEA, and related serum assays, together with the C5000 Dry Micro System, addresses each of these questions directly.

Why Single Serum Tumor Markers Have Limits

tPSA (Total Prostate-Specific Antigen) is used as a prostate cancer screening marker to identify patients who need further investigation after an elevated result. A tPSA level above 4 ng/mL triggers additional testing, but low specificity in benign prostatic hyperplasia and prostatitis can create unnecessary biopsy burden. Because tPSA levels correlate with tumor burden and metastasis risk, the marker remains clinically relevant, but on its own it does not resolve the ambiguity that arises in the 4–10 ng/mL gray zone.

fPSA (Free Prostate-Specific Antigen) was developed as a companion marker to address exactly this gap. When tPSA alone sits in the 4–10 ng/mL range, results are ambiguous and can lead to unnecessary biopsies. By calculating the fPSA/tPSA ratio, with a ratio below 0.16 in that gray zone, prostate cancer detection specificity increases by 17.4% and unnecessary biopsies are reduced. This reflects altered PSA isoforms: fPSA tends to be higher in benign conditions and lower in malignancies.

CEA (Carcinoembryonic Antigen) serves a different role, as a pan-cancer monitoring marker for recurrence and treatment response across colorectal, gastric, pancreatic, lung, and breast cancers. CEA is not diagnostic by itself, since low specificity in smokers and inflammation limits its use as a standalone test; it requires serial measurement and clinical context. Serial postoperative CEA measurements predict recurrence, and a rising CEA level can precede imaging findings, allowing earlier clinical investigation. This is reflected in U.S. clinical practice guidelines, which recommend that a CEA level be obtained before elective colon cancer surgery for post-surgical risk management.

Other serum markers in the portfolio follow the same pattern of individual value paired with individual limitation. AFP has 30–40% false negatives in early hepatocellular carcinoma when used alone. CYFRA21-1 alone shows less positive correlation in NSCLC prognosis. CA19-9 produces false negatives in Lewis antigen-negative individuals, who make up 5–10% of the population. CA125 is elevated in 80% of advanced ovarian cancer cases but only 50% of early-stage cases. Each of these limitations is the reason combined panels exist.

Combined Panels Improve Sensitivity and Specificity

Poclight’s Clinical Combined Detection Solutions compensate for individual marker limitations by pairing markers that address each other’s blind spots. The Prostate Cancer Combined Detection Panel (tPSA + fPSA, F/T ratio) reduces false positives by 30% in the gray zone, with sensitivity of 44–67% and specificity of 81–87%, directly reducing unnecessary biopsies when tPSA is 4–10 ng/mL.

For liver disease, the Hepatocellular Carcinoma Combined Detection Panel (AFP + AFP-L3 + DCP) reaches 70–85% sensitivity and 80–90% specificity, improving on AFP alone for early detection. In lung cancer, two panels serve different purposes: the NSCLC Squamous Combined Detection Panel (CYFRA21-1 + SCC) reaches 88% sensitivity and 74% specificity and helps distinguish squamous carcinoma from adenocarcinoma, while the NSCLC Adenocarcinoma Combined Detection Panel (CEA + CYFRA21-1 + CA125) reaches 75% sensitivity and 70% specificity for early-stage adenocarcinoma detection.

Gastrointestinal panels extend the same logic. The Gastric Cancer Combined Detection Panel (CEA + CA19-9 + CA72-4) achieves 70–86% sensitivity and 80–88% specificity, with CA72-4 specific for gastric origin. The Pancreatic Cancer Combined Detection Panel (CEA + CA19-9 + CA125) reaches 82% sensitivity and 75% specificity, improving on CA19-9 alone and helping predict resectability. The Colorectal Cancer Combined Detection Panel (CEA + CA19-9 + CA242) reaches 70–92% sensitivity and 85–90% specificity, supporting post-surgical monitoring and detection of liver metastases. Finally, the Ovarian Cancer Combined Detection Panel (CA125 + HE4) reaches 76–94% sensitivity, 75–95% specificity, and 93.8% accuracy, supporting early detection and recurrence monitoring beyond what CA125 alone provides.

The C5000 Dry Micro System: A Platform for Quantitative Testing

Quantitative oncology immunoassay results are only as useful as the instrument generating them. The C5000 Dry Micro System is a semi-automatic, portable dry micro detection system designed for rapid serum tumor marker testing. It delivers a first sample result in 3 minutes across a 7-channel capacity, with a throughput of 80 tests/hour and a coefficient of variation below 3%, in a unit weighing no more than 8.5 kg.

The system uses dry micro reagents, with lyophilized reagents suited to room-temperature storage and transport, complemented by liquid reagent formats. Separation is wash-free, with no magnetic beads and no complex liquid path, which reduces operating complexity and cost compared with instruments that rely on those components. More broadly, Poclight’s technical capability metrics describe accuracy with CV below 5% across the platform. Operation is through a touch screen interface, and the system supports LIS/HIS transmission for real-time information sharing, which matters for departments that need results integrated into existing hospital information systems rather than managed separately.

Clinical Consensus Supporting Combined Marker Testing

The rationale behind combined panel testing is not internal to Poclight alone; it is reflected in external clinical guidance referenced across the markers in this portfolio. The PSA Consensus 2024 (UK) states that the PSA blood test is the first step in the prostate cancer diagnostic pathway and describes it as a low-cost, safe, and effective way of identifying men who would benefit from further testing. In the United States, clinical practice guidelines state that a carcinoembryonic antigen (CEA) level should be obtained before elective surgery of colon cancer for risk management afterward. In China, expert consensus on hepatocellular carcinoma screening cost-effectiveness has highlighted biannual ultrasound and AFP as a cost-effective strategy, while a separate meta-analysis concluded that CYFRA21-1 alone shows less positive correlation in NSCLC prognosis, and that combining CEA and SCC helps distinguish early-stage NSCLC from benign lung disease presenting with suspicious pulmonary masses.

A Complete Quantitative Oncology Immunoassay Portfolio

Taken together, Poclight’s offering spans 16 products and services: seven serum tumor marker tests (tPSA, fPSA, CEA, AFP, CYFRA21-1, CA19-9, CA125), eight clinical combined detection panels built from those markers, and the C5000 Dry Micro System that runs them. This portfolio is adapted to Urology, Gastrointestinal Surgery, Gynecology, the Oncology Department, the Respiratory Department, Hepatobiliary Surgery, and Gastroenterology, matching each panel and marker to the clinical setting where it is used for screening, staging, or post-treatment monitoring.

For hospital clinical departments and laboratory environments evaluating quantitative oncology immunoassay testing, the combination of individually characterized serum markers, data-backed combined panels, and a compact 3-minute-result platform with LIS/HIS connectivity gives Poclight’s Tumor Marker line a defined place in the oncology diagnostic pathway, from initial screening markers like tPSA and CEA through to multi-marker panels designed around documented sensitivity and specificity data.

http://www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd

[Author]

Posts